Following the FDA approvals of monoclonal antibodies Leqembi and Kisunla, investment and M&A deals in Alzheimer’s research soared by 780% from $2 billion in 2022 to $18 billion in 2024, according to GlobalData. Pharmaceutical companies, including AbbVie, Sanofi, and Johnson & Johnson, are intensifying focus on disease-modifying therapies targeting amyloid and alternate mechanisms. Despite early commercial challenges, enthusiasm persists for improving treatment efficacy and safety in neurodegenerative disease therapeutics.